ASAIO Journal最新文献_第9页

Predictors of Mortality in Adults With Calcium Channel Blocker Toxicity Receiving Extracorporeal Membrane Oxygenation Support: An Extracorporeal Life Support Organization Registry Analysis. 接受体外膜氧合支持的钙通道阻滞剂毒性成人的死亡率预测因素：体外生命支持组织登记分析》。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-09-16 DOI: 10.1097/MAT.0000000000002307

Rakeshkumar Subramanian, Amelia Roebuck, Hariom Joshi, Michelle Drouin

{"title":"Predictors of Mortality in Adults With Calcium Channel Blocker Toxicity Receiving Extracorporeal Membrane Oxygenation Support: An Extracorporeal Life Support Organization Registry Analysis.","authors":"Rakeshkumar Subramanian, Amelia Roebuck, Hariom Joshi, Michelle Drouin","doi":"10.1097/MAT.0000000000002307","DOIUrl":"10.1097/MAT.0000000000002307","url":null,"abstract":"Calcium channel blocker (CCB) toxicity presents a significant mortality risk, highlighting the need for effective treatment strategies such as extracorporeal membrane oxygenation (ECMO). This study analyzes Extracorporeal Life Support Organization (ELSO) registry data to determine the mortality rate in adults treated with ECMO for CCB toxicity and identifies clinical predictors of mortality. A retrospective analysis of the ELSO registry from January 2016 to April 2023 was conducted, focusing on adults diagnosed with CCB toxicity (ICD-10 T46.1) who received ECMO. Data collected included patient demographics, ECMO details (mode, duration, type), pre-ECMO clinical indicators (pH, lactate levels, cardiac arrest incidence), and in-hospital mortality. The analysis employed descriptive statistics to profile the patient population, with independent t-tests and chi-square tests comparing survivors to nonsurvivors. Logistic regression identified mortality predictors, integrating multiple imputations to remedy missing data, thus ensuring the analysis's integrity. The mortality rate for ECMO-treated CCB toxicity was 40.6%. Severe acidosis and the need for pre-ECMO renal replacement therapy were identified as key predictors of mortality. Further research is needed to determine if early ECMO initiation before a significant pH drop improves outcomes.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"200-203"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Impella 5.5 Reduces Pulmonary Vascular Resistance as Bridge to Heart Transplant in a Pediatric Patient. 使用 Impella 5.5 降低肺血管阻力，为儿科患者的心脏移植架起桥梁。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-06-19 DOI: 10.1097/MAT.0000000000002256

Bradley Oelkers, Erin Schumer, Andrea N Lambert, Bahaaldin Alsoufi, Deborah Kozik, Sarah J Wilkens

引用次数: 0

Development and Evaluation of a Novel Drainage Cannula for Venoarterial Extracorporeal Membrane Oxygenation. 一种新型静脉外膜氧合引流套管的研制与评价。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-12-19 DOI: 10.1097/MAT.0000000000002360

Avishka Wickramarachchi, Saeedreza Zeibi Shirejini, Ashkan Vatani, Akshita Rana, Mehrdad Khamooshi, Michael Šeman, Sam Liao, Edwina Jap, Tuan H Nguyen, Karen Alt, Aidan Burrell, Vincent A Pellegrino, David M Kaye, Christoph E Hagemeyer, Shaun D Gregory

{"title":"Development and Evaluation of a Novel Drainage Cannula for Venoarterial Extracorporeal Membrane Oxygenation.","authors":"Avishka Wickramarachchi, Saeedreza Zeibi Shirejini, Ashkan Vatani, Akshita Rana, Mehrdad Khamooshi, Michael Šeman, Sam Liao, Edwina Jap, Tuan H Nguyen, Karen Alt, Aidan Burrell, Vincent A Pellegrino, David M Kaye, Christoph E Hagemeyer, Shaun D Gregory","doi":"10.1097/MAT.0000000000002360","DOIUrl":"10.1097/MAT.0000000000002360","url":null,"abstract":"A critical factor in thrombus formation during venoarterial extracorporeal membrane oxygenation (VA ECMO) is prothrombotic flow dynamics generated by the drainage cannula's design. This study aimed to create and evaluate a novel drainage cannula design which optimized blood flow dynamics to reduce thrombus formation. Computational fluid dynamics (CFD) was used to iteratively vary drainage cannula design parameters such as inner wall shape and side hole shape. The final novel design was then placed in an ex vivo blood circulation loop, and compared against a Bio-Medicus cannula (n = 6, each). Clot volume, hemolysis, and other parameters were measured to assess thrombus formation markers. The novel design consisted of a parabolic inner wall profile with closely spaced side holes angled at 30º to align with flow. When tested in the ex vivo loop, the novel design resulted in lower instances (two vs . four) and volumes of clot in the cannula (360.5 ± 254.8 vs . 1258.0 ± 651.7 µl) when compared to the Bio-Medicus cannula. Results from tests assessing hemolysis, platelet activation, and other thrombotic markers revealed a noninferior relationship between the novel and Bio-Medicus designs. Future work will explore the clinical applicability of these findings.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"235-244"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Authors' Reply to "Membrane Exchange During ECMO Is Risky Business, but Can It Be Avoided?" 作者对 "ECMO 期间的膜置换风险很大，但能否避免？"的回复

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-09-23 DOI: 10.1097/MAT.0000000000002320

Loic Gouriet, Nicolas De Prost, Paul Masi

引用次数: 0

Clinical Outcomes of Left Ventricular Assist Device Bleeding Complication. 左心室辅助装置出血并发症的临床结果

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-09-24 DOI: 10.1097/MAT.0000000000002317

Shusuke Imaoka, Daisuke Yoshioka, Shunsuke Saito, Takuji Kawamura, Ai Kawamura, Koichi Toda, Shigeru Miyagawa

{"title":"Clinical Outcomes of Left Ventricular Assist Device Bleeding Complication.","authors":"Shusuke Imaoka, Daisuke Yoshioka, Shunsuke Saito, Takuji Kawamura, Ai Kawamura, Koichi Toda, Shigeru Miyagawa","doi":"10.1097/MAT.0000000000002317","DOIUrl":"10.1097/MAT.0000000000002317","url":null,"abstract":"Bleeding complications have emerged as major causes of morbidity and mortality in patients with implantable left ventricular assist devices (LVAD). We hypothesized that the hemodynamics after LVAD implantation may influence the occurrence of bleeding complications after LVAD implantation. We retrospectively evaluated 78 patients who underwent continuous-flow LVAD implantation and hemodynamic ramp test after LVAD implantation between July 2017 and July 2023 at Osaka University. The bleeding complication occurred in 13 patients. The rates of freedom from bleeding complications at 1, 3, and 5 years were 94%, 85%, and 74%. Gastrointestinal bleeding, nose bleeding, and intraperitoneal hemorrhage occurred in six, three, and two patients, respectively. Preoperative average brachial-ankle pulse wave velocity (baPWV) was positively associated with bleeding complication (1,276 ± 280 vs . 1,098 ± 190 cm/s p = 0.04). In the hemodynamic ramp test, systemic vascular resistance (SVR) in patients with bleeding complications was higher than that in patients without bleeding complications (SVR: 1,359 ± 341 vs. 1,150 ± 217 dyne sec/cm 5 , p = 0.01). High preoperative baPWV and high SVR in the hemodynamic ramp test were significantly associated with bleeding complications after LVAD implantation. Arteriosclerosis is a risk factor for bleeding complications after LVAD implantation.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"229-234"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Backwash Maneuver for HeartMate3 Inflow Thrombosis: Experience From Two Cases. 反冲洗法治疗 HeartMate3 血流栓塞：两个病例的经验。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-06-19 DOI: 10.1097/MAT.0000000000002258

Nikolaos Cholevas, Christoph Hoermandinger, Isabell Anna Just, Nikolaos Politis, Volkmar Falk, Evgenij Potapov, Felix Schoenrath

引用次数: 0

Membrane Exchange During ECMO Is Risky Business, but Can It Be Avoided? ECMO 期间的膜置换有风险，但可以避免吗？

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-09-23 DOI: 10.1097/MAT.0000000000002319

Patrick M Wieruszewski, Jamel P Ortoleva

引用次数: 0

Extended Duration of Impella 5.5 Support Does Not Adversely Impact Outcomes Following Heart Transplantation: A National Registry Analysis. 延长 Impella 5.5 支持的持续时间不会对心脏移植后的预后产生不利影响：全国登记分析》。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-08-16 DOI: 10.1097/MAT.0000000000002296

Yeahwa Hong, Ander Dorken-Gallastegi, Umar Nasim, Nicholas R Hess, Luke A Ziegler, Mohamed Abdullah, Nidhi Iyanna, Raj Ramanan, Gavin W Hickey, David J Kaczorowski

{"title":"Extended Duration of Impella 5.5 Support Does Not Adversely Impact Outcomes Following Heart Transplantation: A National Registry Analysis.","authors":"Yeahwa Hong, Ander Dorken-Gallastegi, Umar Nasim, Nicholas R Hess, Luke A Ziegler, Mohamed Abdullah, Nidhi Iyanna, Raj Ramanan, Gavin W Hickey, David J Kaczorowski","doi":"10.1097/MAT.0000000000002296","DOIUrl":"10.1097/MAT.0000000000002296","url":null,"abstract":"Prior studies assessing the effects of Impella 5.5 support duration on posttransplant outcomes have been limited to single-center case reports and series. This study evaluates the impact of Impella 5.5 support duration on outcomes following heart transplantation using the United Network for Organ Sharing database. Adult heart transplant recipients who were directly bridged to primary isolated heart transplantation with Impella 5.5 were included. The cohort was stratified into two groups based on the duration of Impella support: less than or equal to 14 and greater than 14 days. The primary outcome was 90 day posttransplant survival. Propensity score matching was performed. Sub-analysis was conducted to evaluate the impact of greater than 30 days of Impella support on 90 day survival. Three hundred thirty-two recipients were analyzed. Of these, 212 recipients (63.9%) were directly bridged to heart transplantation with an Impella support duration of greater than 14 days. The two groups had comparable 90 day posttransplant survival and complication rates. The comparable posttransplant survival persisted in a propensity score-matched comparison. In the sub-analysis, Impella support duration of greater than or equal to 30 days did not adversely impact 90 day survival. This study demonstrates that extended duration of support with Impella 5.5 as a bridge to transplantation does not adversely impact posttransplant outcomes. Impella 5.5 is a safe and effective bridging modality to heart transplantation.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"213-221"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and Validation of a Novel Pediatric Mechanical Circulatory Support Risk Stratification Tool: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Ventricular Assist Device Score. 新型儿科机械循环支持风险分层工具的开发与验证：高级心脏治疗改善结果网络（ACTION）心室辅助装置评分。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2024-08-16 DOI: 10.1097/MAT.0000000000002297

Carlos Bonilla-Ramirez, Angela Lorts, Joseph A Spinner, Lydia Wright, Robert A Niebler, David M Peng, Ryan R Davies, David N Rosenthal, Matthew J O'Connor

{"title":"Development and Validation of a Novel Pediatric Mechanical Circulatory Support Risk Stratification Tool: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Ventricular Assist Device Score.","authors":"Carlos Bonilla-Ramirez, Angela Lorts, Joseph A Spinner, Lydia Wright, Robert A Niebler, David M Peng, Ryan R Davies, David N Rosenthal, Matthew J O'Connor","doi":"10.1097/MAT.0000000000002297","DOIUrl":"10.1097/MAT.0000000000002297","url":null,"abstract":"We sought to develop and validate a new risk stratification score for mortality for children supported with a ventricular assist device (VAD). This retrospective, multicenter study used data from patients undergoing VAD implantation between April 2018 and February 2023 at 44 participating institutions in the Advanced Cardiac Therapies Improving Outcomes (ACTION) network. Multivariable Cox proportional-hazards modeled mortality after VAD implantation. A total of 1,022 patients were enrolled. The 1 year mortality was 19% (95% confidence interval [CI]: 16-23). The multivariable model was used to build the ACTION VADs risk stratification score with four components: ventilation, advanced organ support (dialysis or ECMO), diagnosis, and size (weight ≤5 kg). One point is added for each risk factor. Based on the sum of the risk factors, patients were classified into four classes: class 0-green (4% mortality at 1 year), class 1-yellow (16% mortality at 1 year), class 2-orange (21% mortality at 1 year), and class 3 or higher-red (42% mortality at 1 year). The score performed well, with area under the curve (AUC) of 0.72 and excellent calibration. The ACTION VADs score for mortality can be calculated easily and offers risk stratification and prognostic information for pediatric VAD candidates. This is the first validated risk assessment tool for pediatric mechanical circulatory support.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"270-275"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meet the Authors. 见见作者。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI: 10.1097/01.mat.0001108648.53678.be

引用次数: 0